Navegando por Palavras-chave "pharmacogenomics"

Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Effect of APOE and CHRNA7 Genotypes on the Cognitive Response to Cholinesterase Inhibitor Treatment at Different Stages of Alzheimer's Disease
    (Sage Publications Inc, 2015-03-01) Sampaio Braga, Ianna Lacerda [UNIFESP]; Silva, Patricia Natalia [UNIFESP]; Furuya, Tatiane Katsue [UNIFESP]; Santos, Leonardo Caires [UNIFESP]; Pires, Belisa Caldana [UNIFESP]; Mazzotti, Diego Robles [UNIFESP]; Bertolucci, Paulo Henrique [UNIFESP]; Cendoroglo, Maysa Seabra [UNIFESP]; Smith, Marilia Cardoso [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    The loss of cholinergic transmission is considered to be an important cause of Alzheimer's disease (AD). Treatment with acetyl cholinesterase inhibitors (ChEIs) shows benefits; however, great heterogeneity has been observed in patient responses. We evaluated apolipoprotein E (APOE) and 7 nicotinic receptor (CHRNA7) single-nucleotide polymorphisms (SNPs) and associated these SNPs with pharmacological responses to ChEIs in a Brazilian population with AD. We studied 177 outpatients using ChEIs, and they were classified as responders and nonresponders according to variation in Mini-Mental State Examination (MMSE) status. the analysis of APOE genotypes showed that patients with the 4 allele had a worse response than those without the 4 allele. We observed an association between the CHRNA7 T allele and a better response to treatment with ChEIs in patients with mild AD (MMSE 20). the SNP rs6494223 of CHRNA7 as well as APOE4 could be useful for understanding the response to ChEI treatment in patients with AD.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis
    (Expert Reviews, 2008-07-01) Okamoto, Oswaldo Keith [UNIFESP]; Perez, Jose Fernando [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    This review discusses some of the impacts that biotechnology, genomics and nanotechnology convergence should have on future cancer management, in particular, the development of innovative diagnostic and therapeutic approaches based on monoclonal antibodies (mAbs) and cancer stem cells. Emergent therapeutic strategies in cancer have been focusing on the use of mAbs to stimulate an immune response against tumors, to block signaling pathways, or to refine delivery of cytotoxic agents. Now that cancer stem cells are being identified and characterized in different tumor types, their relevance to cancer physiopathology is becoming evident, making them natural targets for mAb development. Cancer stem cells are postulated to be responsible for tumor development, metastasis and relapse after conventional therapies. Therefore, mAbs targeting specific antigens and related pathways altered in cancer stem cells should facilitate earlier diagnosis through molecular imaging techniques and more efficient destruction of tumor initiating cells, thus improving clinical outcome.